Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.

about

Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.

Item

http://www.wikidata.org/entity/Q54367194

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Impact of systemic treatment o ...... atients with brain metastases.

@en

Impact of systemic treatment o ...... atients with brain metastases.

@nl

type

Item

label

Impact of systemic treatment o ...... atients with brain metastases.

@en

Impact of systemic treatment o ...... atients with brain metastases.

@nl

prefLabel

Impact of systemic treatment o ...... atients with brain metastases.

@en

Impact of systemic treatment o ...... atients with brain metastases.

@nl

P1476

Impact of systemic treatment o ...... patients with brain metastases

@en

P2093

Adam Pawinski

http://www.w3.org/2001/XMLSchema#string

Astrid Dalhaug

http://www.w3.org/2001/XMLSchema#string

Carsten Nieder

http://www.w3.org/2001/XMLSchema#string

Gro Aandahl

http://www.w3.org/2001/XMLSchema#string

Kirsten Marienhagen

http://www.w3.org/2001/XMLSchema#string

P2860

Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years?

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline.

Evidence-based guidelines for the management of brain metastases.

P2888

s12032-014-0927-2

P304

927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-014-0927-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ellinor Haukland

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24647787

http://www.w3.org/2001/XMLSchema#string